237 related articles for article (PubMed ID: 19152631)
21. Quantitative structure-activity relationship studies on inhibition of HERG potassium channels.
Yoshida K; Niwa T
J Chem Inf Model; 2006; 46(3):1371-8. PubMed ID: 16711756
[TBL] [Abstract][Full Text] [Related]
22. Development and evaluation of an in silico model for hERG binding.
Song M; Clark M
J Chem Inf Model; 2006; 46(1):392-400. PubMed ID: 16426073
[TBL] [Abstract][Full Text] [Related]
23. Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
Imai YN; Ryu S; Oiki S
J Med Chem; 2009 Mar; 52(6):1630-8. PubMed ID: 19260734
[TBL] [Abstract][Full Text] [Related]
24. Topological mapping of the asymmetric drug binding to the human ether-à-go-go-related gene product (HERG) potassium channel by use of tandem dimers.
Myokai T; Ryu S; Shimizu H; Oiki S
Mol Pharmacol; 2008 Jun; 73(6):1643-51. PubMed ID: 18326583
[TBL] [Abstract][Full Text] [Related]
25. A QSAR model of HERG binding using a large, diverse, and internally consistent training set.
Seierstad M; Agrafiotis DK
Chem Biol Drug Des; 2006 Apr; 67(4):284-96. PubMed ID: 16629826
[TBL] [Abstract][Full Text] [Related]
26. Computer simulations of structure-activity relationships for HERG channel blockers.
Boukharta L; Keränen H; Stary-Weinzinger A; Wallin G; de Groot BL; Aqvist J
Biochemistry; 2011 Jul; 50(27):6146-56. PubMed ID: 21657256
[TBL] [Abstract][Full Text] [Related]
27. Predictive in silico modeling for hERG channel blockers.
Aronov AM
Drug Discov Today; 2005 Jan; 10(2):149-55. PubMed ID: 15718164
[TBL] [Abstract][Full Text] [Related]
28. Support vector machines classification of hERG liabilities based on atom types.
Jia L; Sun H
Bioorg Med Chem; 2008 Jun; 16(11):6252-60. PubMed ID: 18448342
[TBL] [Abstract][Full Text] [Related]
29. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.
Perrin MJ; Kuchel PW; Campbell TJ; Vandenberg JI
Mol Pharmacol; 2008 Nov; 74(5):1443-52. PubMed ID: 18701618
[TBL] [Abstract][Full Text] [Related]
30. GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Ermondi G; Visentin S; Caron G
Eur J Med Chem; 2009 May; 44(5):1926-32. PubMed ID: 19110341
[TBL] [Abstract][Full Text] [Related]
31. Assessing hERG channel inhibition using PatchXpress.
Ly JQ; Shyy G; Misner DL
Clin Lab Med; 2007 Mar; 27(1):201-8. PubMed ID: 17416313
[TBL] [Abstract][Full Text] [Related]
32. The Catch-22 of Predicting hERG Blockade Using Publicly Accessible Bioactivity Data.
Siramshetty VB; Chen Q; Devarakonda P; Preissner R
J Chem Inf Model; 2018 Jun; 58(6):1224-1233. PubMed ID: 29772901
[TBL] [Abstract][Full Text] [Related]
33. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
34. Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues.
Louvel J; Carvalho JF; Yu Z; Soethoudt M; Lenselink EB; Klaasse E; Brussee J; Ijzerman AP
J Med Chem; 2013 Dec; 56(23):9427-40. PubMed ID: 24224763
[TBL] [Abstract][Full Text] [Related]
35. APETx1 from sea anemone Anthopleura elegantissima is a gating modifier peptide toxin of the human ether-a-go-go- related potassium channel.
Zhang M; Liu XS; Diochot S; Lazdunski M; Tseng GN
Mol Pharmacol; 2007 Aug; 72(2):259-68. PubMed ID: 17473056
[TBL] [Abstract][Full Text] [Related]
36. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools.
Moorthy NS; Ramos MJ; Fernandes PA
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):317-24. PubMed ID: 23560722
[TBL] [Abstract][Full Text] [Related]
37. Toxins interacting with ether-à-go-go-related gene voltage-dependent potassium channels.
Wanke E; Restano-Cassulini R
Toxicon; 2007 Feb; 49(2):239-48. PubMed ID: 17097705
[TBL] [Abstract][Full Text] [Related]
38. Support vector machine-based quantitative structure-activity relationship study of cholesteryl ester transfer protein inhibitors.
Riahi S; Pourbasheer E; Ganjali MR; Norouzi P
Chem Biol Drug Des; 2009 May; 73(5):558-71. PubMed ID: 19323654
[TBL] [Abstract][Full Text] [Related]
39. Prediction of ion channel activity using binary kernel discrimination.
Willett P; Wilton D; Hartzoulakis B; Tang R; Ford J; Madge D
J Chem Inf Model; 2007; 47(5):1961-6. PubMed ID: 17622131
[TBL] [Abstract][Full Text] [Related]
40. Predictive models for HERG channel blockers: ligand-based and structure-based approaches.
Thai KM; Ecker GF
Curr Med Chem; 2007; 14(28):3003-26. PubMed ID: 18220737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
